Jakafi XR payer formulary ramp: 50%-70% coverage target by end-2026 with wins at major PBMs and regional plans.
Opzelura moderate atopic dermatitis launch in Europe expected in Q3 2026.
Povorcitinib moderate-to-severe HS approvals and launch expected late 2026 in Europe and Q1 2027 in the U.S.
Monjuvi first-line DLBCL regulatory review with anticipated approvals and launches into 2027.
989 mutant CALR antibody Phase III initiation in JAK-experienced myelofibrosis expected in H2 2026.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Incyte Corporation and 4,900+ companies.